1.	Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TLK199.1101, NCT00280631
2.	Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TLK199.1001, NCT00035867
3.	Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TLK199.2101, NCT00700206
4.	Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Phase: Phase II Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TLK199.2103, NCT00909584
5.	Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TLK199.1104, NCT01062152